• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma.

作者信息

Tang Xin, Wang Yuelong, Huang Jianhan, Zhang Zongliang, Liu Fujun, Xu Jianguo, Guo Gang, Wang Wei, Tong Aiping, Zhou Liangxue

机构信息

Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China.

State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China.

出版信息

Signal Transduct Target Ther. 2021 Mar 26;6(1):125. doi: 10.1038/s41392-021-00505-7.

DOI:10.1038/s41392-021-00505-7
PMID:33767145
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7994554/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8bc/7994554/fcfe3a43869c/41392_2021_505_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8bc/7994554/fcfe3a43869c/41392_2021_505_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8bc/7994554/fcfe3a43869c/41392_2021_505_Fig1_HTML.jpg

相似文献

1
Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma.给予靶向B7-H3的嵌合抗原受体T细胞可诱导胶质母细胞瘤消退。
Signal Transduct Target Ther. 2021 Mar 26;6(1):125. doi: 10.1038/s41392-021-00505-7.
2
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.B7-H3 重定向嵌合抗原受体 T 细胞靶向神经胶质瘤和神经球。
EBioMedicine. 2019 Sep;47:33-43. doi: 10.1016/j.ebiom.2019.08.030. Epub 2019 Aug 26.
3
Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model.颅内注射 B7-H3 靶向 Car-T 和 Car-NK 细胞在患者来源的胶质母细胞瘤异种移植模型中的抗肿瘤作用。
Cancer Immunol Immunother. 2024 Oct 5;73(12):256. doi: 10.1007/s00262-024-03808-0.
4
Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.武装杀伤性T细胞：洞悉过继性T细胞转移在胶质母细胞瘤中的作用
Immunotherapy. 2015;7(5):481-5. doi: 10.2217/imt.15.22.
5
Locoregional delivery of chimeric antigen receptor-T cells: Breaking the spell in glioblastoma?嵌合抗原受体T细胞的局部区域递送：打破胶质母细胞瘤的魔咒？
Neuro Oncol. 2024 Jul 5;26(7):1177-1180. doi: 10.1093/neuonc/noae063.
6
Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.嵌合抗原受体 T 细胞疗法：胶质母细胞瘤治疗的新进展。
Neurosurgery. 2021 May 13;88(6):1056-1064. doi: 10.1093/neuros/nyaa584.
7
Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.嵌合抗原受体 T 细胞免疫疗法治疗胶质母细胞瘤：神经外科医生的实用见解。
Neurosurg Focus. 2018 Jun;44(6):E13. doi: 10.3171/2018.2.FOCUS17788.
8
CAR T cells offer hope in glioblastoma.嵌合抗原受体T细胞为胶质母细胞瘤带来了希望。
Nat Rev Neurol. 2024 Jun;20(6):315. doi: 10.1038/s41582-024-00972-w.
9
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.优化针对 IL13Rα2 的嵌合抗原受体 T 细胞，以提高对神经胶质瘤的抗肿瘤疗效。
Mol Ther. 2018 Jan 3;26(1):31-44. doi: 10.1016/j.ymthe.2017.10.002. Epub 2017 Oct 5.
10
Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.嵌合抗原受体 T 细胞疗法治疗多形性胶质母细胞瘤的研究进展。
Cancer Med. 2021 Aug;10(15):5019-5030. doi: 10.1002/cam4.4064. Epub 2021 Jun 19.

引用本文的文献

1
Cellular immunotherapies for central nervous system cancers.用于中枢神经系统癌症的细胞免疫疗法。
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv84-iv94. doi: 10.1093/noajnl/vdaf120. eCollection 2025 Sep.
2
CAR-T cell therapy for glioblastoma: advances, challenges, and future directions.胶质母细胞瘤的嵌合抗原受体T细胞疗法：进展、挑战与未来方向
Ann Med Surg (Lond). 2025 Jul 18;87(9):5743-5756. doi: 10.1097/MS9.0000000000003607. eCollection 2025 Sep.
3
CAR T cell therapy for central nervous system solid tumors: current progress and future directions.

本文引用的文献

1
B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma.B7-H3作为胶质母细胞瘤的新型嵌合抗原受体T细胞（CAR-T）治疗靶点
Mol Ther Oncolytics. 2019 Jul 23;14:279-287. doi: 10.1016/j.omto.2019.07.002. eCollection 2019 Sep 27.
2
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.单次外周输注靶向表皮生长因子受体III型变异体（EGFRvIII）的嵌合抗原受体（CAR）T细胞可介导抗原缺失，并在复发性胶质母细胞瘤患者中诱导适应性耐药。
Sci Transl Med. 2017 Jul 19;9(399). doi: 10.1126/scitranslmed.aaa0984.
3
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
中枢神经系统实体瘤的嵌合抗原受体T细胞疗法：当前进展与未来方向
Front Immunol. 2025 Aug 15;16:1600403. doi: 10.3389/fimmu.2025.1600403. eCollection 2025.
4
Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy.克服胶质母细胞瘤中的障碍：嵌合抗原受体T细胞免疫疗法的潜力。
Theranostics. 2025 Jun 12;15(14):7090-7126. doi: 10.7150/thno.114257. eCollection 2025.
5
Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications.用编码嵌合抗原受体的狒狒包膜假型慢病毒载体转导γδ T细胞，用于转化研究和临床应用。
Front Immunol. 2025 Jun 6;16:1548630. doi: 10.3389/fimmu.2025.1548630. eCollection 2025.
6
Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors.不断发展嵌合抗原受体T细胞疗法以克服治疗小儿中枢神经系统肿瘤的障碍。
Cancer Discov. 2025 May 2;15(5):890-902. doi: 10.1158/2159-8290.CD-24-1465.
7
Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma.前列腺素F2受体负调控因子作为胶质母细胞瘤嵌合抗原受体T细胞疗法的潜在靶点。
Cancer Immunol Immunother. 2025 Mar 6;74(4):136. doi: 10.1007/s00262-025-03979-4.
8
Political economics in health and implications for neurosurgery diseases.卫生领域的政治经济学及其对神经外科疾病的影响。
Front Public Health. 2025 Jan 28;12:1444249. doi: 10.3389/fpubh.2024.1444249. eCollection 2024.
9
Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma.针对嵌合抗原受体（CAR）功能的联合筛选鉴定出用于治疗胶质母细胞瘤的新型靶向白细胞介素-13受体α2（IL-13Rα2）的CAR
J Immunother Cancer. 2025 Feb 11;13(2):e009574. doi: 10.1136/jitc-2024-009574.
10
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial.用于弥漫性脑桥内在型胶质瘤的脑室内靶向B7-H3嵌合抗原受体T细胞：一项1期试验
Nat Med. 2025 Mar;31(3):861-868. doi: 10.1038/s41591-024-03451-3. Epub 2025 Jan 7.
嵌合抗原受体T细胞疗法后胶质母细胞瘤的消退
N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497.
4
Differential expression of 2IgB7-H3 and 4IgB7-H3 in cancer cell lines and glioma tissues.2IgB7-H3和4IgB7-H3在癌细胞系和胶质瘤组织中的差异表达。
Oncol Lett. 2015 Oct;10(4):2204-2208. doi: 10.3892/ol.2015.3611. Epub 2015 Aug 14.
5
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.IL13Rα2定向嵌合抗原受体CD8+T细胞在复发性胶质母细胞瘤患者中的生物活性和安全性
Clin Cancer Res. 2015 Sep 15;21(18):4062-72. doi: 10.1158/1078-0432.CCR-15-0428. Epub 2015 Jun 9.